Recombinant Human Neuregulin Derivatives and Use Thereof
AssigneeZensun (Shanghai) Science & Technology, Co., Ltd.
InventorMingdong Zhou
Life of this patent
Estimating the term…
Abstract
Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.
Claims10
An NRG fusion polypeptide, comprising an amino acid sequence of an EGF-like domain of NRG and an amino acid sequence of an IgG Fc or Fc analogue.
Use of an NRG fusion polypeptide in the manufacture of a medicament for preventing, treating or relieving cardiovascular diseases in mammals.
A pharmaceutical formulation, comprising an NRG fusion polypeptide and a pharmaceutically acceptable carrier, excipient or diluent, wherein the NRG fusion polypeptide comprises an amino acid sequence of an EGF-like domain of NRG, and an amino acid sequence of an IgG Fc or Fc analogue.
A method of treating cardiovascular diseases, comprising administering an effective dose of an NRG fusion polypeptide in an individual in need thereof, wherein the NRG fusion polypeptide comprises an amino acid sequence of an EGF-like domain of NRG, and an amino acid sequence of an IgG Fc or Fc analogue.
Dependencies are inferred from the claim text.